출혈성 질환 검사 시장 : 제품별, 적응증별, 최종 용도별, 예측(2023-2032년)

Global Bleeding Disorder Testing Market is set to record a decent growth rate between 2023 and 2032, driven by the rising prevalence of bleeding disorders, such as hemophilia and von Willebrand disease, increasing the demand for accurate and efficient diagnostic testing.

Consistent technological breakthroughs in the field have led to the development of specialized tests for bleeding disorders, enhancing diagnostic capabilities. Additionally, the growing awareness and screening initiatives for early detection and management of bleeding disorders contribute to market growth. Moreover, a favorable regulatory framework leading to increased R&D investments and the development of novel therapeutic options will favor market growth.

The overall bleeding disorder testing market is classified based on product, indication, end-use, and region.

With regard to the product category, the instrument segment could amass a notable market share by 2032. The increasing prevalence of bleeding disorders necessitates accurate and reliable diagnostic tools. Advancements in technology have led to the development of specialized instruments that provide precise and efficient testing. Besides, the rising awareness and early detection efforts for bleeding disorders contribute to the demand for these instruments in clinical settings.

Based on indication, the bleeding disorder testing market size from the hemophilia B segment will depict an appreciable CAGR from 2023 to 2032. The high incidence rate of hemophilia B, a genetic bleeding disorder, drives the need for accurate and timely diagnosis. Advancements in diagnostic technologies have improved the efficiency and accuracy of hemophilia B testing. Additionally, the growing awareness of the condition and the availability of treatment options contribute to the rising demand for hemophilia B testing.

In terms of end-user, the hospitals & clinics segment will capture a sizeable share of the bleeding disorder testing industry by 2032. Hospitals and clinics serve as primary healthcare providers and diagnostic centers, handling a large volume of patients with bleeding disorders. Secondly, the increasing prevalence of bleeding disorders necessitates accurate and efficient testing services, which hospitals and clinics can provide. Additionally, advancements in diagnostic technologies and the availability of specialized healthcare professionals in these settings contribute to their role as major end-users for bleeding disorder testing.

Europe bleeding disorder testing industry will drive noticeable gains through 2032. The surging incidences of bleeding disorders in the region necessitates improved diagnostic capabilities. The implementation of favorable government policies and initiatives focused on early detection and management of bleeding disorders contributes to market growth. Additionally, advancements in healthcare infrastructure, increasing healthcare expenditure, and growing awareness about bleeding disorders further fuel the demand for testing services in Europe.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Industry coverage
• 1.2 Market scope & definition
• 1.3 Base estimates & calculations
  • 1.3.1 Data collection
• 1.4 Forecast parameters
• 1.5 COVID-19 impact analysis at global level
• 1.6 Data validation
• 1.7 Data Sources
  • 1.7.1 Primary
  • 1.7.2 Secondary
    • 1.7.2.1 Paid sources
    • 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Bleeding disorder testing industry 360 degree synopsis, 2018 - 2032
• 2.2 Business trends
• 2.3 Regional trends
• 2.4 Product type trends
• 2.5 Indication trends
• 2.6 End-use trends

Chapter 3 Bleeding Disorder Testing Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of blood disorders
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Supportive awareness initiatives
    • 3.2.1.4 Recent product approvals
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of skilled professionals
• 3.3 Growth potential analysis
  • 3.3.1 By product
  • 3.3.2 By indication
  • 3.3.3 By end use
• 3.4 COVID- 19 impact analysis
• 3.5 Pricing analysis, 2022, by region
  • 3.5.1 North America
    • 3.5.1.1 U.S.
    • 3.5.1.2 Canada
  • 3.5.2 Europe

.3.5.2.1. Germany

• 3.5.2.2 UK
• 3.5.2.3 France
• 3.5.2.4 Spain
• 3.5.2.5 Italy
• 3.5.2.6 Poland
• 3.5.2.7 Switzerland
• 3.5.2.8 The Netherlands
• 3.5.3 Asia Pacific
  • 3.5.3.1 Japan
  • 3.5.3.2 China
  • 3.5.3.3 India
  • 3.5.3.4 Australia
  • 3.5.3.5 South Korea
  • 3.5.3.6 Indonesia
  • 3.5.3.7 Philippines
  • 3.5.3.8 Vietnam
• 3.5.4 Latin America
  • 3.5.4.1 Brazil
  • 3.5.4.2 Mexico
  • 3.5.4.3 Argentina
  • 3.5.4.4 Columbia
  • 3.5.4.5 Chile
  • 3.5.4.6 Peru
• 3.5.5 MEA
  • 3.5.5.1 South Africa
  • 3.5.5.2 Saudi Arabia
  • 3.5.5.3 UAE
  • 3.5.5.4 Israel
  • 3.5.5.5 Egypt
  • 3.5.5.6 Turkey
• 3.6 Regulatory landscape
  • 3.6.1 U.S.
  • 3.6.2 Europe
• 3.7 Reimbursement scenario
  • 3.7.1 U.S.
• 3.8 Technological advancements
• 3.9 Gap analysis
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Global company market share analysis, 2022
• 4.4 Vendor matrix analysis
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Bleeding Disorder Testing Market Size and Forecast, By Product Type (USD Million & Units)

• 5.1 Key trends, by product type
• 5.2 Reagents & consumbales
• 5.3 Instruments

Chapter 6 Bleeding Disorder Testing Market Size and Forecast, By Indication (USD Million)

• 6.1 Key trends, by indication
• 6.2 Hemophilia A
• 6.3 Hemophilia B
• 6.4 Von Willebrand Disease
• 6.5 Idiopathic Thrombocytopenic Purpura
• 6.6 Others

Chapter 7 Bleeding Disorder Testing Market Size and Forecast, By End-use (USD Million)

• 7.1 Key trends, by end-use
• 7.2 Hospitals & clinics
• 7.3 Diagnostic centers
• 7.4 Others

Chapter 8 Bleeding Disorder Testing Market Size and Forecast, By Region (USD Million)

• 8.1 Key trends, by region
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Poland
  • 8.3.7 Switzerland
  • 8.3.8 The Netherlands
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Indonesia
  • 8.4.7 Philippines
  • 8.4.8 Vietnam
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Columbia
  • 8.5.5 Chile
  • 8.5.6 Peru
• 8.6 MEA
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Israel
  • 8.6.5 Egypt
  • 8.6.6 Turkey

Chapter 9 Company Profiles

• 9.1 Siemens Healthineers
• 9.2 F Hoffmann-La Roche Ltd
• 9.3 Abbott Laboratories
• 9.4 Bio-Rad Laboratories, Inc
• 9.5 Thermo Fisher Scientific Inc
• 9.6 Grifols SA
• 9.7 Sysmex Corporation
• 9.8 Werfen
• 9.9 Cephied (Danaher Corporation)
• 9.10 HORIBA Ltd
• 9.11 Hyphen Biomed
• 9.12 Precision Biologics Inc.
• 9.13 Atlas Medical GmbH
• 9.14 PreventionGenetics (Exact Sciences Corp)
• 9.15 Blueprint Genetics Oy
• 9.16 American Biochemical & Pharmaceuticals Limited
• 9.17 DiaPharma